
FDA Approves Giredestrant Plus Everolimus in ESR1-Mutated Breast Cancer
Key Takeaways
- FDA approved giredestrant plus everolimus for ER-positive/HER2-negative, ESR1-mutated advanced disease, contingent on ESR1 detection by an FDA-authorized assay, with FoundationOne Liquid CDx authorized as companion diagnostic.
- Phase 3 evERA randomized 373 patients (207 ESR1-mutated); ESR1 status was centrally determined via ctDNA, and premenopausal women/men received GnRH agonist unless orchiectomized.
The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.
The FDA has approved giredestrant (Wilserdly), an oral selective estrogen receptor degrader (SERD), in combination with everolimus (Afinitor) for adults with estrogen receptor (ER)–positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.¹ The indication covers disease that has recurred during or after endocrine-based adjuvant therapy, or that has progressed on at least 1 endocrine-based regimen in the metastatic setting, and ESR1 mutation status must be detected by an FDA-authorized test.
The agency also authorized the FoundationOne Liquid CDx assay as a companion diagnostic to identify patients with ESR1 mutations for treatment with giredestrant. The application was reviewed under Project Orbis with Health Canada and Israel’s Ministry of Health, and the FDA approved it 4 weeks ahead of its goal date.
Trial Design and Efficacy
The approval is based on the randomized, open-label, multicenter phase 3 evERA trial (NCT05306340), which enrolled 373 adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer, including 207 patients with ESR1-mutated tumors. ESR1 status was assessed centrally using circulating tumor DNA.
Patients were randomly assigned 1:1 to giredestrant 30 mg daily plus everolimus 10 mg daily (n = 183) or to physician’s choice of endocrine therapy (exemestane, fulvestrant, or tamoxifen) plus everolimus 10 mg daily (n = 190).¹ Premenopausal women and men received a GnRH agonist, except men who had undergone bilateral orchiectomy, and treatment continued until disease progression or unacceptable toxicity.
The major efficacy end point in the ESR1-mutated population was investigator-assessed progression-free survival (PFS) per RECIST 1.1.¹ Giredestrant plus everolimus reduced the risk of progression or death by 62% vs the comparator (HR, 0.38; 95% CI, 0.27-0.54; P < .0001).¹ Median PFS was 10 months (95% CI, 8.1-12.9) with giredestrant plus everolimus vs 5.5 months (95% CI, 3.8-5.6) with physician’s choice of endocrine therapy plus everolimus.
The objective response rate was 27% (95% CI, 18%-37%) vs 14% (95% CI, 8%-22%), respectively.¹ Overall survival data were immature at the time of the PFS analysis.
Safety and Dosing
The most common adverse reactions, occurring in at least 20% of patients, were stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea. The most common laboratory abnormalities (≥20%) were decreased hemoglobin, lymphocytes, white blood cells, neutrophils, platelets, calcium, potassium, and sodium, along with increased aspartate aminotransferase, alanine aminotransferase, and creatinine. Warnings and precautions include bradycardia and embryo-fetal toxicity.
The recommended dose of giredestrant is 30 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. Prescribers should refer to the everolimus prescribing information for its dosing.
Regulatory Background
The FDA accepted the
REFERENCES
1. FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. News release. FDA. November 16, 2026. Accessed November 16, 2026.
2. FDA accepts new drug application for Genentech’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer. News release. Genentech. February 19, 2026. Accessed November 16, 2026.
3. FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting. News release. Genentech. June 2, 2026. Accessed November 16, 2026.
Related to this article







